

US Capital Global Announces \$35 Million Equity Offering for iosBio's Groundbreaking Oral Vaccine Platform



A unique investment opportunity in iosBio, a UK-based biotech company revolutionizing vaccine delivery with thermostable, self-administered vaccines—beginning with a \$12.6B market opportunity in Epstein-Barr virus.

SAN FRANCISCO, MAY 2025 – US Capital Global Securities LLC, an SEC-registered affiliate of global financial group **US Capital Global**, is excited to present eligible investors with the opportunity to participate in a \$35 million equity offering for iosBio Limited ("iosBio" or the "Company").

iosBio is a UK-based biotechnology company that is transforming the future of immunization with its proprietary OraPro™ platform, which enables the development of next-generation oral vaccines. The Company's innovative vaccines are thermostable and self-administered, eliminating the need for cold-chain storage and injection. iosBio's pipeline includes vaccines targeting high unmet needs, such as Epstein-Barr virus, COVID-19, influenza, Zika, and Nipah, with a clear path to clinical advancement.

"We're fundamentally changing the way vaccines are delivered," said **Wayne Channon**, Executive Chairman of iosBio. "From preclinical successes to expanding our intellectual property portfolio and building a world-class team, iosBio is poised for transformative growth. With a \$12.6 billion market opportunity in Epstein-Barr virus alone, we believe our approach is well-positioned to disrupt global immunization efforts."



Dr. Prodi Bhattacharya, Managing Director and Partner at US Capital Global, added, “iosBio’s oral, shelf-stable vaccine platform offers a bold new approach to immunization, breaking down logistical barriers and enabling global access. With strong leadership, an expanding patent portfolio, and a sharp focus on high-value targets like Epstein-Barr virus, iosBio is an exciting opportunity for innovation-driven investors. We are thrilled to support their next phase of growth with this \$35 million equity offering, and **we invite eligible investors to participate in this promising opportunity.**”

About iosBio Limited

Based in Haywards Heath, UK, iosBio is a preclinical-stage biotechnology company developing oral, thermostable vaccines that eliminate the need for cold-chain storage and injection. By leveraging its OraPro™ platform, iosBio delivers vaccines in easy-to-administer capsule form, making global distribution more accessible—especially in low-resource settings. The Company holds multiple issued patents and is advancing its Epstein-Barr vaccine candidate through clinical trials. For more information, visit www.iosbio.com.

About US Capital Global

US Capital Global Securities LLC (“USCGS”) serves as the FINRA-member broker-dealer division of US Capital Global, specializing in facilitating growth-stage investments. Since 1998, US Capital Global has been dedicated to providing lower middle market businesses and investors with sophisticated investment opportunities. For further details about US Capital Global Securities or this investment opportunity, contact Pankaj Vashisth, Managing Director of Capital Markets and Partner, at pv@uscapital.com or call +1 415-999-0310.

Disclaimer: USCGS or its affiliates may provide advice to, be compensated by, have other business relationships with, or may from time to time acquire, hold, or sell a position in the securities of the issuers mentioned herein. Any offer or solicitation shall be made only pursuant to the confidential private placement memorandum. View USCGS’ Form CRS at www.uscapglobalsecurities.com/crs.html.